453 related articles for article (PubMed ID: 31031746)
1. Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.
Brandsma AM; Bondza S; Evers M; Koutstaal R; Nederend M; Jansen JHM; Rösner T; Valerius T; Leusen JHW; Ten Broeke T
Front Immunol; 2019; 10():704. PubMed ID: 31031746
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
3. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing.
Brandsma AM; Ten Broeke T; Nederend M; Meulenbroek LA; van Tetering G; Meyer S; Jansen JH; Beltrán Buitrago MA; Nagelkerke SQ; Németh I; Ubink R; Rouwendal G; Lohse S; Valerius T; Leusen JH; Boross P
Cancer Immunol Res; 2015 Dec; 3(12):1316-24. PubMed ID: 26407589
[TBL] [Abstract][Full Text] [Related]
6. FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.
Treffers LW; van Houdt M; Bruggeman CW; Heineke MH; Zhao XW; van der Heijden J; Nagelkerke SQ; Verkuijlen PJJH; Geissler J; Lissenberg-Thunnissen S; Valerius T; Peipp M; Franke K; van Bruggen R; Kuijpers TW; van Egmond M; Vidarsson G; Matlung HL; van den Berg TK
Front Immunol; 2018; 9():3124. PubMed ID: 30761158
[TBL] [Abstract][Full Text] [Related]
7. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
8. IgGA: a "cross-isotype" engineered human Fc antibody domain that displays both IgG-like and IgA-like effector functions.
Kelton W; Mehta N; Charab W; Lee J; Lee CH; Kojima T; Kang TH; Georgiou G
Chem Biol; 2014 Dec; 21(12):1603-9. PubMed ID: 25500223
[TBL] [Abstract][Full Text] [Related]
9. Immunoglobulin A: magic bullet or Trojan horse?
Heineke MH; van Egmond M
Eur J Clin Invest; 2017 Feb; 47(2):184-192. PubMed ID: 28024097
[TBL] [Abstract][Full Text] [Related]
10. Augmented antibody-based anticancer therapeutics boost neutrophil cytotoxicity.
Heemskerk N; Gruijs M; Temming AR; Heineke MH; Gout DY; Hellingman T; Tuk CW; Winter PJ; Lissenberg-Thunnissen S; Bentlage AE; de Donatis M; Bögels M; Rösner T; Valerius T; Bakema JE; Vidarsson G; van Egmond M
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33561014
[TBL] [Abstract][Full Text] [Related]
11. IgA Fc receptor I signals apoptosis through the FcRgamma ITAM and affects tumor growth.
Kanamaru Y; Tamouza H; Pfirsch S; El-Mehdi D; Guérin-Marchand C; Pretolani M; Blank U; Monteiro RC
Blood; 2007 Jan; 109(1):203-11. PubMed ID: 16990604
[TBL] [Abstract][Full Text] [Related]
12. IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.
Duchemin M; Khamassi M; Xu L; Tudor D; Bomsel M
Front Immunol; 2018; 9():244. PubMed ID: 29651286
[TBL] [Abstract][Full Text] [Related]
13. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.
Otten MA; Rudolph E; Dechant M; Tuk CW; Reijmers RM; Beelen RH; van de Winkel JG; van Egmond M
J Immunol; 2005 May; 174(9):5472-80. PubMed ID: 15843545
[TBL] [Abstract][Full Text] [Related]
14. Pneumococcal capsular polysaccharide-specific IgA triggers efficient neutrophil effector functions via FcalphaRI (CD89).
van der Pol W; Vidarsson G; Vilé HA; van de Winkel JG; Rodriguez ME
J Infect Dis; 2000 Oct; 182(4):1139-45. PubMed ID: 10979910
[TBL] [Abstract][Full Text] [Related]
15. Myeloid cells as effector cells for monoclonal antibody therapy of cancer.
Braster R; O'Toole T; van Egmond M
Methods; 2014 Jan; 65(1):28-37. PubMed ID: 23811299
[TBL] [Abstract][Full Text] [Related]
16. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.
Mullarkey CE; Bailey MJ; Golubeva DA; Tan GS; Nachbagauer R; He W; Novakowski KE; Bowdish DM; Miller MS; Palese P
mBio; 2016 Oct; 7(5):. PubMed ID: 27703076
[TBL] [Abstract][Full Text] [Related]
17. Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockade.
Chan C; Stip M; Nederend M; Jansen M; Passchier E; van den Ham F; Wienke J; van Tetering G; Leusen J
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782540
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory ITAM signaling by Fc alpha RI-FcR gamma chain controls multiple activating responses and prevents renal inflammation.
Kanamaru Y; Pfirsch S; Aloulou M; Vrtovsnik F; Essig M; Loirat C; Deschênes G; Guérin-Marchand C; Blank U; Monteiro RC
J Immunol; 2008 Feb; 180(4):2669-78. PubMed ID: 18250479
[TBL] [Abstract][Full Text] [Related]
19. IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.
Treffers LW; Ten Broeke T; Rösner T; Jansen JHM; van Houdt M; Kahle S; Schornagel K; Verkuijlen PJJH; Prins JM; Franke K; Kuijpers TW; van den Berg TK; Valerius T; Leusen JHW; Matlung HL
Cancer Immunol Res; 2020 Jan; 8(1):120-130. PubMed ID: 31690649
[TBL] [Abstract][Full Text] [Related]
20. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
